Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease

7/25/24 1:47:08 AM ET

$SNY

$TEVA

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SNY alert in real time by email

Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment
Topline results for both UC and CD now anticipated in Q4 2024
Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug (anti-TL1A) for moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD) patients

Get the next $SNY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SNY
$TEVA

Company	Date	Price Target	Rating	Analyst
Sanofi $SNY	7/26/2024	$55.00 → $60.00	Buy	Argus
Teva Pharmaceutical Industries Limited $TEVA	7/10/2024	$20.00	Hold → Buy	Argus
Teva Pharmaceutical Industries Limited $TEVA	3/8/2024	$14.00	Underweight → Neutral	JP Morgan
Teva Pharmaceutical Industries Limited $TEVA	2/12/2024	$12.00 → $19.00	Neutral → Overweight	Piper Sandler
Teva Pharmaceutical Industries Limited $TEVA	1/23/2024	$10.00 → $14.00	Hold → Buy	Jefferies
Sanofi $SNY	1/23/2024	$55.00	Equal-Weight	Morgan Stanley
Sanofi $SNY	1/16/2024		Buy	UBS
Teva Pharmaceutical Industries Limited $TEVA	1/3/2024	$8.00 → $12.00	Underweight → Neutral	Piper Sandler

More analyst ratings

$SNY
$TEVA
Financials

Live finance-specific insights

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023.AUSTEDO® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion.AJOVY® – global revenues of $137 million in Q3 2024, an increase of 21% in local currency terms compared to Q3 2023.UZEDY® is gaining momentum – U.S. revenues of $35 million in Q3 2024; raising 2024 revenues outlook from ~$80 million to ~$100 million.Early and late-stage innovative pipeline continues to progress, with duv
11/6/24 7:00:00 AM ET
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations Following the conclusion of the call, a replay of the webcast will be availabl
9/30/24 4:30:00 PM ET
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
For an accessible version of this Press Release, please visit www.tevapharm.com Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local currency terms compared to Q2 2023.Generics business grows across all regions – increased in local currency terms by 16% in the U.S., 8% in Europe and 22% in International Markets, compared to Q2 2023.AUSTEDO – continued growth, U.S. revenue of $407 million in Q2 2024, an increase of 32% compared to Q2 2023; raising 2024 revenue outlook to ~$1.6 billion.AJOVY® – global revenues of $115 million in Q2 2024, an increase of 12% in local currency terms compared to Q2 2023.Announced acceleration of developme
7/31/24 7:00:00 AM ET
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care

$SNY
$TEVA
Press Releases

Fastest customizable press release news feed in the world

Teva to Present at the Jefferies London Healthcare Conference
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmac
11/8/24 4:30:00 PM ET
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023.AUSTEDO® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion.AJOVY® – global revenues of $137 million in Q3 2024, an increase of 21% in local currency terms compared to Q3 2023.UZEDY® is gaining momentum – U.S. revenues of $35 million in Q3 2024; raising 2024 revenues outlook from ~$80 million to ~$100 million.Early and late-stage innovative pipeline continues to progress, with duv
11/6/24 7:00:00 AM ET
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person's underlying mental health conditionRegistry revealed fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%)Teva continues to further innovations in mental health and progress real-world data to improve treatment optimization TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim
11/1/24 3:05:00 PM ET
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care

$SNY
$TEVA
Leadership Updates

Live Leadership Updates

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical
6/6/24 7:00:00 AM ET
$AZN
$IMAB
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2
5/15/24 8:15:00 AM ET
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: "I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business. We're confident that this strategy will result in a more focused end-to-end operation, and I am confident tha
11/7/23 4:30:00 PM ET
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
On Thursday, Sanofi SA (NASDAQ:SNY) reported a second-quarter business operating income of 2.8 billion euros ($3.03 billion), up 3.2% year-over-year and 8.3% in constant currency. The company reported second-quarter sales of $11.57 billion (10.75 billion euros), beating the consensus of $11.37 billion. Sales increased 7.8% year over year and 10.2% on constant currency. Also Read: Europe Approves Sanofi/Regeneron’s Dupixent for ‘Smoker’s Lungs’ A Month After US FDA Asks For Data. The French drugmaker reported adjusted EPS of $0.93 (1.73 euros), beating the consensus estimate of $0.86, down 0.6% reported and up 4.0% at CER. Sales of Dupixent, Sanofi’s blockbuster eczema drug, rose
7/25/24 8:20:12 AM ET
$AZN
$REGN
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Sanofi shares are trading higher following a Q2 earnings beat.
7/25/24 8:17:08 AM ET
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech space could once again drag the broader market after a few disappointing earnings reports from the likes of Franco-Italian chipmaker STMicroelectronics N.V. (NYSE:STM), which predominantly supplies to the automotive end market, and semiconductor test-equipment company Teradyne, Inc. (NASDAQ:TER). Traders may also stay glued to second-quarter GDP data to confirm the slowdown suggested by some recent data does not point to a hard landing. That said, bond yields are dipping as the market, factori
7/25/24 7:23:10 AM ET
$AAL
$ABBV
$AZN
$BJRI
Air Freight/Delivery Services
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care

Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease

Chat with this insight

Recent Analyst Ratings for $SNY$TEVA

$SNY$TEVA Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

Amendment: SEC Form SC 13G/A filed by Sanofi

SEC Form SC 13G filed by Sanofi

$SNY$TEVA FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

FDA Approval for ADLYXIN issued to SANOFI-AVENTIS US

FDA Approval for SARCLISA issued to SANOFI AVENTIS US

$SNY$TEVA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Argus reiterated coverage on Sanofi with a new price target

Teva Pharma upgraded by Argus with a new price target

Teva Pharma upgraded by JP Morgan with a new price target

$SNY$TEVA Financials

Live finance-specific insights

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance

$SNY$TEVA SEC Filings

SEC Form 6-K filed by Sanofi

SEC Form 8-K filed by Teva Pharmaceutical Industries Limited

SEC Form 6-K filed by Sanofi

$SNY$TEVA Press Releases

Fastest customizable press release news feed in the world

Teva to Present at the Jefferies London Healthcare Conference

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

$SNY$TEVA Leadership Updates

Live Leadership Updates

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

$SNY$TEVA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Head of U.S. Commercial Fox Christine converted options into 63,492 units of Ordinary Shares and sold $327,085 worth of Ordinary Shares (19,388 units at $16.87) (SEC Form 4)

Director Shalev Varda converted options into 12,872 units of Ordinary Shares (SEC Form 4)

Exec. VP, European Commercial Daniell Richard sold $1,711,447 worth of Ordinary Shares (98,943 units at $17.30), closing all direct ownership in the company (SEC Form 4)

$SNY$TEVA Market Insights

Live Market Insights

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand

Sanofi shares are trading higher following a Q2 earnings beat.

Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House

Recent Analyst Ratings for
$SNY
$TEVA

$SNY
$TEVA
Large Ownership Changes

$SNY
$TEVA
FDA approvals

$SNY
$TEVA
Analyst Ratings

$SNY
$TEVA
Financials

$SNY
$TEVA
SEC Filings

$SNY
$TEVA
Press Releases

$SNY
$TEVA
Leadership Updates

$SNY
$TEVA
Insider Trading

$SNY
$TEVA
Market Insights